莫沙必利联合复方消化酶治疗功能性消化不良  

Combined Therapy of Mosapride and Compound Digestive Enzymes for Functional Dyspepsia

作　　者：江汉龙[1] 金峰[1] 石晋[1] 颜艳[1] 

机构地区：[1]南京军区福州总医院476临床部消化肿瘤科,福州350002

出　　处：《华西医学》2010年第3期471-473,共3页West China Medical Journal

摘　　要：目的观察莫沙必利联合复方消化酶胶囊治疗功能性消化不良的临床疗效和安全性。方法 2008年1月-2009年7月对62例功能性消化不良患者随机分为两组,每组31例,两组均口服莫沙必利片,三餐饭前30min服用5mg;试验组加服复方消化酶胶囊,进餐后30min服用1粒。4周后观察疗效。结果试验组治疗总有效率明显优于对照组,分别为87.1%和61.3%(P<0.05)。对上腹痛、餐后饱胀、早饱、上腹烧灼感症状改善情况进行比较,试验组治疗前后的症状总积分及症状改善有效率与对照组比较差异有统计学意义(P<0.05),而且起效时间明显缩短。两组患者均未发现严重不良反应。结论莫沙必利联合复方消化酶胶囊治疗功能性消化不良安全有效,其疗效明显优于单用促动力药莫沙必利。Objective To study the efficacy and safety of combined therapy of mosapride and compound digestive enzymes for functional dyspepsia. Methods Sixty-two patients with functional dyspepsia were randomized into experimental group （n= 31） and the controls （n= 31） from January 2008 to July 2009. The patients in the control group were only given mosapride 5 mg for 3 times per day, 30 min before meals for 4 weeks. The patients in the experimental group were given 1 capsule of compound digestive enzymes for 3 times per day, 30 min after meals in addition to mosapride for 4 weeks too. The therapeutic efficacy and side effects were compared between the two groups by chi square test. Results The general therapeutic efficacy in the experimental group was superior to the controls （87.1% vs 61.3%, P〈0.05）. The symptoms, such as upper abdominal pain, abdominal distention, early satiety and stomach burn in the patients in the experimental group were more improved than in the control group （P〈0. 05）. The experimental group had shown shorter action onset time than the controls. No severe side effects were found in the both groups. Conclusion Combined therapy of mosapride and compound digestive enzymes can more significantly iraprove general efficacy and symptoms in patients with functional dyspepsia than single use of motility medicine mosa pride.

关 键 词：功能性消化不良 莫沙必利 复方消化酶 

分 类 号：R57[医药卫生—消化系统]